Latest Updates

Widely hailed as the future of phase II drug development, the adaptive I-SPY2 platform trial has set a new benchmark for efficiency, through innovation in trial design and clinical operations.
Close
Close
I-SPY Email List Sign-up

Latest Press Releases

View All
SABCS 2017: Long-term efficacy results from the I-SPY 2 TRIAL indicate pathological complete response (pCR) is a powerful predictor for breast cancer survival

Data Presented at San Antonio Breast Cancer Symposium Show Significant and Clinically Impactful Relationship Between pCR and Event-Free Survival in High-Risk Breast Cancer.

Press Release

December 7, 2017

SABCS 2017: I-SPY 2 TRIAL predictive biomarker analysis shows promise to improve targeted therapy for high-risk breast cancers

New Data Analyses Presented at San Antonio Breast Cancer Symposium Spotlight Predictive Response to Pembrolizumab and MK-2206, and Demonstrate Improved Predictive Performance of Breast MRI.

Press Release

December 7, 2017

Natera's Personalized CtDNA Technology Now Part Of I-SPY 2 TRIAL

With this new technology, the I-SPY 2 TRIAL can better help match agents, combinations, and additional targeted interventions to women with high-risk breast cancers.

Press Release

August 21, 2017

Latest Announcements

View All
I-SPY 2 TRIAL featuring three abstracts at ASCO's 2018 Annual Meeting

Three results from I-SPY’s adaptive trial design being showcased at ASCO 2018.

Announcement

May 30, 2018

Dr. Laura Esserman Honored: OncLive® To Induct the 2018 Class of Giants of Cancer Care®

OncLive® announced Dr. Laura Esserman as an inductee of the 2018 Giants of Cancer Care® recognition program.

Announcement

May 26, 2018

Healio Mentions I-SPY 2 Trial In "Five Updates For Triple Negative Breast Cancer Day"

In conjunction with Triple Negative Breast Cancer Day, HemOnc Today presents five updates in the treatment of triple-negative breast cancer and on associated disparities that may impact your practice.

Announcement

March 3, 2017

Latest News Coverage

View All